Biocon to merge Biocon Biologics in $5.5 billion deal
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Granules Consumer Health serves as Granules’ front-end division for OTC products in the US
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)
Subscribe To Our Newsletter & Stay Updated